Carregant...
Fitxers
Tipus de document
ArticleData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/174864
Efficacy and safety of direct-acting antiviral agents when combined with secukinumab
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: The interference in the immune response induced by biological disease-modifying antirheumatic drugs (bDMARDs) increases the risk of reactivation of infections. Treatment of patients with chronic hepatitis C virus (HCV) infection and psoriasis is complex. The efficacy and safety of the new direct-acting antiviral agents (DAA) when combined with bDMARDs remain unknown. Case report: We present a case of a 44-year-old Caucasian man affected with psoriasis and HCV infection. Throughout the course of the psoriatic disease, this patient received several lines of treatment, including secukinumab, a new type of bDMARD. At the time of commencing secukinumab, new DAA agents (ledipasvir/sofosbuvir) were also initiated. At week 12 post-treatment, hepatitis C viral load was undetectable and the patient remained in remission of psoriasis. Conclusion: This case report suggests that secukinumab is a therapeutic option in patients with psoriasis, particularly in those cases with HCV infection where treatment with DAA agents is warranted.
Matèries (anglès)
Citació
Col·leccions
Citació
MARTÍNEZ SANTANA, Virginia, RODRÍGUEZ MURPHY, Esther, SMITHSON AMAT, Alejandro, MISERACHS ARANDA, Nuria, RÍO-GIL, Ruben del, TORRE LLOVERÁS, Inmaculada. Efficacy and safety of direct-acting antiviral agents when combined with secukinumab. _European Journal Of Hospital Pharmacy-Science And Practice_. 2018. Vol. 25, núm. 1, pàgs. 53-56. [consulta: 28 de gener de 2026]. ISSN: 2047-9956. [Disponible a: https://hdl.handle.net/2445/174864]